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Abstract
The antioxidant properties of a-tocopherol have been proposed to play a beneficial chemopreventive role against cancer.
However, emerging data also indicate that it may exert contrasting effects on the efficacy of chemotherapeutic treatments
when given as dietary supplement, being in that case harmful for patients. This dual role of a-tocopherol and, in particular,
its effects on the efficacy of anticancer drugs remains poorly documented. For this purpose, we studied here, using high
throughput flow cytometry, the direct impact of a-tocopherol on apoptosis and cell cycle arrest induced by different
cytotoxic agents on various models of cancer cell lines in vitro. Our results indicate that physiologically relevant
concentrations of a-tocopherol strongly compromise the cytotoxic and cytostatic action of various protein kinase inhibitors
(KI), while other classes of chemotherapeutic agents or apoptosis inducers are unaffected by this vitamin. Interestingly,
these anti-chemotherapeutic effects of a-tocopherol appear to be unrelated to its antioxidant properties since a variety of
other antioxidants were completely neutral toward KI-induced cell cycle arrest and cell death. In conclusion, our data
suggest that dietary a-tocopherol could limit KI effects on tumour cells, and, by extent, that this could result in a reduction
of the clinical efficacy of anti-cancer treatments based on KI molecules.
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Introduction
Vitamin E was first described in 1922 as a dietary factor in
animal nutrition [1]. It includes two groups (tocopherols and
tocotrienols) of related fat soluble benzopyranol compounds, that
are naturally found in vegetable oils [2]. It is also generally present
as additive in industrially prepared foods and drinks and is
declared in this case under the codes E306 to 309. In tocopherols,
the C16 side chain is saturated while in tocotrienols, it contains
three double bonds. Each group contains four constituents termed
alpha (5,7,8-trimethyl), beta (5,8-dimethyl), gamma (7,8-dimethyl)
and delta (8-methyl).
Since decades, vitamin E supplementation has been shown to
possess beneficial effects for atherosclerosis, ischemic heart
disease and cancer [3–5]. It is commonly assumed that these
effects are linked to the antioxidant properties of these phenolic
compounds [2,6]. Vitamin E acts as a hydrophobic chain-
breaking antioxidant that exerts a protective role against free
radical damage to unsaturated lipids and hence membranes and
tissues. Nevertheless, the sole antioxidant properties are
presumably not sufficient to explain all the effects played by
these molecules [2], and actually, in the past ten years, non-
antioxidant functions of these agents have been described. Some
authors have, for instance, reported pro-oxidant properties of a-
tocopherol, showing that LDL peroxydation was faster in
presence of this compound [7,8]. Inhibition of PKC activity
by a-tocopherol has also been shown to have a key role on
vascular smooth muscle cell growth arrest [9,10] and since,
many papers have confirmed this effect on many other cell
types such as monocytes, macrophages, neutrophils, fibroblast-
s and mesangial cells [11–14]. In activated human monocytes,
a-tocopherol is also responsible for the decrease of proinflam-
matory cytokine IL-1b release via the inhibition of the 5-
lipoxygenase pathway [15]. It is interesting to note that beta-
tocopherol and trolox, contrary to a-tocopherol, do not possess
these inhibitory properties [16,17]. Gene expression could also
be modulated by a-tocopherol, but not by beta-tocopherol.
Some data have notably emphasized the ability of a-tocopherol
to up-regulate the expression of tropomyosin gene [18] and
down-regulate the expression of smooth muscle cells scavenger
receptor gene (CD36), at the transcriptional level [19].
Beside these various properties, recent clinical trials on
antioxidants supplementation have led to contradictory results.
A meta-analysis by Bjelakovic et al. have showed, in particular,
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does not have a beneficial effect on mortality but would rather
increase the risk of death [20]. Even among vitamin E
compounds, differences can be seen between tocotrienols and
tocopherols. The former has indeed been shown to be a potent
anticancer agent while the latter does not exhibit antitumoral
activity even at extremely high concentrations [21]. The
influence of antioxidants on the efficacy of anticancer treatments
can thus be questioned since the induction of cell death by
cytotoxic therapies usually holds an oxidative stress component
that may be reduced by antioxidants. If it seems relatively
intuitive for radiotherapy, the contribution of an oxidative stress
in the mechanism of action of chemotherapeutic drugs used in
clinic remains less clear. However, in vitro, the existence of a
ROS-mediated amplification loop of cytotoxic effects has been
evoked for different molecules such as DNA-damage inducing
agents [22], TNF-a [23] or kinase inhibitors [24]. As a-
tocopherol addition significantly reduced apoptosis induced by
TNF-a, 7-ketocholesterol or nicotine in lymphoma or pulmo-
nary epithelial cells, it was suggested that the protective role of
the vitamin was a result of its anti-oxidative properties [21]. But
unexpectedly, tocotrienols have opposite effects and potently
induce apoptosis, suggesting that tocopherols and tocotrienols
harbour distinctive intrinsic properties, and may act indepen-
dently of their antioxidative capacities.
To better understand the mechanism of action of a-tocopherol,
we conducted here a series of in vitro experiments specifically
designed to monitor the real influence of a-tocopherol on the
effects of various cytotoxic agents. We followed the effects of a-
tocopherol addition on apoptosis and cell proliferation arrest
induced by different agents. Our results show that a-tocopherol
has an inhibitory effect on cytotoxic response, which is indepen-
dent of its antioxidant potential.
Results
a-Tocopherol Inhibits Apoptosis Depending on Cell
Death Inducers
To elucidate which are the real repercussions of a-tocopherol
addition on cell death, we determined the dose-response curves
of different proapoptotic inducers in presence or not of the
vitamin. Three different models of death-inducing pathways
were tested in order to discriminate between a general or a
specific effect of a-tocopherol on cell demise: camptothecin and
etoposide were used as DNA damage inducers [25,26], TNF-a
the key mediator of inflammatory pathologies, was selected as a
model of death-receptor mediated apoptosis and staurosporine
(STS) was chosen as a pan kinase inhibitor, whose mechanism
of action depends on the concentration of cellular exposure.
Cell death was monitored using a GFP-based recombinant
probe that measures the intracellular DEVDase activity, a
specific marker of caspase-dependent apoptosis [27]. With this
approach we evaluated the impact of antioxidant treatments
specifically on the early steps of cell death. In HeLa cells, we
found that the presence of a-tocopherol does not modify the
dose-response curves of camptothecin, etoposide or TNF-abut
in contrast that it strongly inhibits cell death triggered by STS
(Figure 1A–D). Indeed, a-tocopherol drastically reduces the
percentage of caspase-3 positive cells post STS-treatment,
increasing EC50 from 52 nM to 805 nM (Figure 1D). In
addition, this protective effect of a-tocopherol against STS-
induced cell death did not appear to be cell specific, as it was
also observed on DU145 prostate cancer cells with a ten time
increase in EC50 (Figure 1E).
a-Tocopherol Protection from STS-induced Apoptosis
does not Depend on its Antioxidant Properties
We first hypothesized that contrary to DNA damage or death
receptor mediated cell death, STS toxicity would include a major
oxidative stress component leading to caspase activation, and that
this event would be blockable by the anti-oxidative properties of a-
tocopherol. To verify this, we repeated the same experiments with
three other antioxidants: trolox, NAC (N-acetyl cystein) and
propofol (Figure 2). Contrary to a-tocopherol, trolox, a water-
soluble vitamin E derivative, was not able to block STS-induced
cell death. As presented in Figure 2A, the dose-response curves
showing the percentage of cells with activated caspase-3 post-STS
treatment perfectly fit in absence or in presence of three different
concentrations of trolox (30, 100 and 300 mM). The same was
observed with NAC (Figure 2C) and with propofol, a highly
lipophilic anaesthetic drug that exhibits antioxidant potency
similar to a-tocopherol (Figure 2E) [28]. Indeed, STS EC50 for
caspase activation was neither modified after NAC nor after
propofol addition. To confirm this intriguing result, we also
evaluated the effect of trolox, NAC and propofol on later steps of
apoptosis i.e on cell membrane permeability (cytolysis) (Figure 2B,
2D) and chromatin condensation (Figure 2F). Again, no protective
effect of these antioxidants on cell death was observed (Figure 2A–
F), while zVAD, a pan caspase-inhibitor, strongly reduced the
percentage of STS-induced DEVDase activity or cytolysis
(Figure 2G). This was also verified by western blot looking at
PARP protein, a direct substrate of activated caspases. As shown in
Figure 2I, a-tocopherol was as efficient as zVAD to block STS-
induced PARP cleavage, contrary to NAC. Of note, zVAD alone
also displayed some activity against the endogenous level of
cleaved PARP, which indicates that a basal level of activated
caspases resides in healthy cells. As a-tocopherol did not affect this
background level of cleaved PARP, we concluded that this vitamin
is certainly not a direct inhibitor of caspases (as also indirectly
shown by the differential effect of a-tocopherol towards TNF-a,
etoposide, camptothecin versus STS-induced cell death - in
Figure 1). Finally, despite the ability of all the antioxidants tested
here to reduce the production of ROS triggered by STS
(Figure 2H), only a-tocopherol significantly blocked STS-mediated
cell death, suggesting that this particular molecule can hold, under
certain circumstances, potent anti-apoptotic properties that are
independent of its antioxidant capacities.
a-Tocopherol also Inhibits STS Effects on Proliferation
and Cell Cycle Arrest
STS is a pan kinase inhibitor that can act on several protein
kinases including those involved in cell cycle regulation. This drug
is generally known as an apoptotic inducer but, at lower
concentrations, it also leads to cell growth arrest. Accordingly,
we found that, in HeLa cells, STS triggered an inhibition of cell
proliferation with an EC50 of 17 nM (Figure 3A). In these
conditions, a-tocopherol addition rendered cells far less sensitive to
STS-mediated cell cycle arrest. As presented in Figure 3A, STS
EC50 for cell proliferation increased in a dose-dependent manner
in presence of the vitamin (EC50 was respectively multiply by 2, 20
and 40 in presence of 30, 100 and 300 mMo fa-tocopherol
compared to STS alone). On the contrary, the addition of another
antioxidant, trolox, had no effect (Figure 3B).
We then stained HeLa cells for cell cycle profile and determined
that STS provoked a blockade in G2/M phase that was overcome
by a-tocopherol addition (Figure 3C). We finally showed that a-
tocopherol prevented the accumulation of cells with condensed
nuclei (at 24 h) or multilobes nuclei (at 48 h) that usually occurs in
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chromosomal replication (Figure 3D). As above, none of the other
antioxidants tested (trolox, tempol, NAC, Euk8 and propofol) -nor
the p38 inhibitor SB203580- were able to annihilate STS-induced
cell cycle arrest (Figure 3B, D, E). Thus, as observed for apoptosis,
a-tocopherol inhibited the antiproliferative properties of STS,
while other antioxidants did not. To explore more in depth how a-
tocopherol protected STS-treated cells from death, we sought to
determine whether a-tocopherol effects were dependent on a
transcriptional activity, as a direct action of a-tocopherol on gene
expression has previously been described [18]. However, as shown
in Figure 3F, the addition of cycloheximide, an inhibitor of protein
synthesis, did not abrogate the ability of the vitamin to block STS-
induced cell death, suggesting that the protective effect of a-
tocopherol does not rely on a transcriptional mechanism, but is
more direct. Of particular interest, it seemed that a-tocopherol
was not only able to protect cells from STS-mediated apoptosis,
but also to stimulate cell proliferation in a dose-dependent
manner. HeLa cells proliferation index was, for instance, 2.5
times higher in a culture media supplemented with 300 mMo fa-
tocopherol than without (Figure 3G). So, it is possible that a-
tocopherol engages proliferative pathways and stimulates them
sufficiently enough to counteract the blockage of cell cycle
triggered by STS treatment.
a-Tocopherol Effects on other Kinase Inhibitors
Our results show that a-tocopherol specifically blocks STS-
induced cell death. In order to explore the specificity of this
pharmacological interaction and determine if this effect can be
generalized to other kinase inhibitors, we repeated the same
experiments with several other drugs belonging to this class of
molecules. We first analysed benzoyl-STS, a derivative of STS
evaluated in phase I, phase II and one on-going phase III clinical
trial [29,30]. Similarly to STS, benzoyl-STS is a multi kinase
inhibitor (PKC, VEGFR-2, PDGFR, KIT, MDR and FLT-3) [31]
that triggers apoptosis in a dose-dependent manner, but with a
higher EC50 (639 nM) (Figure 4A). As for STS, a-tocopherol
exerted a significant protection against benzoyl-STS-induced
Figure 1. a-tocopherol inhibits staurosporine but not camptothecin, TNF-a or etoposide-induced apoptosis. In all cases, a-tocopherol
was added simultaneously to drug treatment. A–D Dose response curves obtained for camptothecin (A), TNF-a supplemented with 10 mMo f
cycloheximide (CHX) (B), etoposide (C) and STS (D) in response to a-tocopherol treatment (100 mM) in a clone of HeLa cells stably expressing a
caspase3/7-differential anchorage probe (C3/7-DAP). E Dose response of STS in a clone of DU145 (prostate carcinoma) expressing a C3/7-DAP was
determined in presence or absence of a-tocopherol treatment (100 mM). In each case, EC50 were determined and are presented below the dose-
response curves.
doi:10.1371/journal.pone.0036811.g001
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Trolox, at the opposite, had no effect (EC50=490 nM). At low
concentrations, benzoyl-STS also induced a cell cycle arrest in
G2/M that was totally prevented by the addition of a-tocopherol
but not by trolox, exactly as observed with STS (Figure 4B). Two
cell cycle kinases inhibitors were then studied: roscovitine and
flavopiridol. Both drugs belong to the family of cyclin-dependent
kinase (CDK) inhibitors and are under clinical development.
While flavopiridol effects on cell cycle (that appeared to be
moderate) did not seem to be sensitive toa-tocopherol, roscovitine
dependent-G2/M blockade was highly reversed by a-tocopherol
addition (Figure 4C and 4D). To finally ascertain that a-
tocopherol was also efficient towards CDK inhibitors, we tested
it on a new CDK inhibitor developed by Servier, named S37614.
This drug, that preferentially targets CDK7, promotes caspase
activation and apoptosis with an interesting EC50 (EC50=6.1 mM)
(Figure 4E). Contrary to other antioxidants such as NAC
(EC50=5.6 mM) and trolox (EC50=5.5 mM), a-tocopherol
showed again a strong potential to protect cells that were
committed to S37614-dependent cell death (EC50=32.3 mM)
(Figure 4E). In addition, as described above, a-tocopherol also
prevented S37614 effects on cell proliferation (Figure 4F). S37614
EC50 for cell proliferation was indeed multiply by 3 in presence of
a-tocopherol, increasing from 513 nM to 1 675 nM. Other
antioxidants did not exert such a protection: EC50 in presence of
NAC, propofol or trolox being respectively equal to 487 nM,
520 nM and 264 nM. Thus, a-tocopherol exhibited an inhibitory
effect on both S37614 pro-apoptotic and antiproliferative prop-
erties. Altogether, atocopherol showed a strong inhibition against
all kinase inhibitors tested except flavopiridol whose effect was
weaker. These results, rather astonishing, underlie the non-
negligible antagonist action of a-tocopherol on various kinase
inhibitors, and raise the question of such consequences in a clinical
context.
a-Tocopherol Compromises the Effects of KI used in
Clinical Practice
To finally assess the effects of a-tocopherol addition on various
cytotoxic drugs used in clinical practice, we chose to work with two
different models of cancer cell lines that exhibit a relevant kinase-
dependent transformed phenotype and for which protein kinase
inhibitors are currently used as therapeutics. The first one
corresponded to K562 cell line, a model of Chronic Myelogenous
Leukemia (CML) characterized by the presence of the oncogenic
BCR-ABL fusion protein that possesses a higher tyrosine kinase
activity than the normal c-Abl protein and thus drives the aberrant
proliferation and malignancy of these cells [32]. As an ideal
candidate for targeted therapy, several drugs have been developed
against BCR-ABL, among which the frontline therapy for CML,
imatinib (or Gleevec) [33] and the second generation BCR-ABL
inhibitors (also efficient on imatinib resistant form of BCR-ABL)
nilotinib (Tasigna) [34,35] and dasatinib (Sprycel) [36]. The
second model corresponded to PC-9 cell line, a human lung
adenocarcinoma driven by the oncogenic activation of the EGFR
pathway caused by a deletion (Del E746–A750) in the exon 19 of
the EGFR [37]. The presence of such a deletion has been found to
be associated with a higher sensitivity to gefitinib (Iressa) or
erlotinib (Tarceva), two selective EGFR kinase inhibitors
[38,39,40]. We found that a co-incubation of a-tocopherol with
imatinib or nilotinib prevented the anti-proliferative action of
these drugs on K562 cells (Figure 5 A, B). Indeed, while the
addition of 10 to 30 mM of imatinib or nilotinib induced a slow
down of cell proliferation with a delay of one to two cell cycle(s) of
division compared to control cells (DiI staining being, according
the time point, 2 to 3 times less fluorescent in control cells than in
imatinib or nilotinib cells), a-tocopherol supplementation signifi-
cantly reverted this effect. In respect to that result, we also found
that gefitinib’s action could be counteracted by the presence of a-
tocopherol in PC-9 cells. Both the antiproliferative and cytotoxic
activities of this KI were indeed reduced by the vitamin (Figure 5
C, D). Despite significant, the effects of a-tocopherol on these
therapeutic compounds were slightly lower than for STS, probably
due to their different way of action. Nonetheless, in certain
conditions, a-tocopherol clearly delays or annihilates their antic-
ancerous properties. Altogether, these data strongly suggest that a-
tocopherol addition could, under certain circumstances of drug
and vitamin concentrations, block the beneficial action of various
kinase inhibitors used as novel targeted therapy in clinical practice,
meaning that a-tocopherol could be critically involved in
therapeutic failure.
Discussion
a-tocopherol constitutes a vitamin E compound whose antiox-
idant properties are well known for decades. These interesting
properties have led many investigators and clinicians to utilize this
molecule in adjuvant supplementation diet to protect cells and
tissues from free radical damage and oxidative stress. But recently,
clinical trials on antioxidants supplementation have led to
controversial results, showing that vitamin E, instead of being
protective, would increase the risk of death [20,41–43]. This states
that the role of vitamin E is not totally understood and that some
of its properties may counteract its protective effects. It also
remains possible that vitamin E is more efficient as a preventive
molecule rather than as a curative adjuvant. In that sense, we
demonstrated here that a-tocopherol is able to inhibit the
antiproliferative and proapoptotic effects of different chemother-
apeutic agents and that this effect is not dependent on its
antioxidant properties.
STS is a commonly used PKC inhibitor that is well known to
trigger apoptosis in a large panel of cell lines [44–46]. In this work,
Figure 2. a-tocopherol protects from staurosporine-induced cell death independently of its antioxidant properties. When co-
treatments were needed, antioxidants were added simultaneously to STS. A, C, E HeLa cells stably expressing a C3/7-DAP were treated with
increasing amounts of STS in presence or not of different concentrations of trolox (A), NAC (C) or propofol (E). Dose response curves were established
accordingly and EC50 values are presented below the curves. B, D HeLa cells were treated for 24 h with increasing amounts of STS in presence or not
of trolox (B) and NAC (D) before measuring the percentage of cytolyzed cells using EMA staining. Dose response curves and EC50 values are shown
below. F HeLa cells were treated with increasing amounts of STS in presence or not of propofol for 24 h. The percentage of subG1 cells was
quantified after propidium iodide staining and dose response curves done accordingly. EC50 values are shown below. G DEVDase activity- and
cytolysis- dose response curves in response to STS with or without the addition of zVAD, a pan caspase inhibitor. The number of cells was determined
24 h post-drugs treatment. H Quantification of ROS production in HeLa cells treated with vehicle or 30 nM of STS in presence or not of different
antioxidants such as propofol (30 mM), a-tocopherol (100 mM), and tempol (100 mM) measured 24 hours after treatment using DCFDA as described in
Materials and Methods. I Hela cells were treated with DMSO or 100 nM of STS in presence or not of 100 mMo fa-tocopherol, 10 mM of NAC or
100 mM of zVAD for 24 hours. Apoptotic cell death was then evaluated by immunoblotting using an anti-cleaved PARP antibody. Actin was used as a
loading control.
doi:10.1371/journal.pone.0036811.g002
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36811Figure 3. a-tocopherol prevents staurosporine-mediated cell cycle arrest in an antioxidant independent manner. A, B DiI-stained
HeLa cells were treated with increasing amounts of STS supplemented with vehicle or 30, 100 and 300 mMo fatocopherol (A) or trolox (B) for 48
hours. Cell proliferation dose response curves were established from the median intensity fluorescence of DiI obtained for each point and normalized
to the untreated control cells. EC50 values are shown in the table below the curves. C HeLa cells, co-treated with STS (1, 10, 30, 100 nM) and a-
tocopherol (0, 100 or 300 mM) were stained with propidium iodide and cell cycle profile was determined by flow cytometry. The ratio of the
percentage of cells in G2M on the percentage of cells in G0G1 was calculated and is shown here as a measure of the cell cycle profile variation. D
HeLa cells were co-treated with 0.1 mM of STS and vehicle, a-tocopherol (100 mM) or NAC (3 mM) for 24 h or 48 h. Cells were fixed and colored with
Hoechst. Images were acquired using the LSM510 confocal microscope. E HeLa cells were left untreated (black bars) or treated with 100 nM of STS for
a-Tocopherol Reduces Various KI Anticancer Effects
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way, both the antiapoptotic and antiproliferative properties of
STS. A similar observation has been described by a group in 2000
[47] on primary cultures of chick embryonic neurons. This study
revealed a protective effect of tocopherol against STS-induced
neuronal apoptosis, presumably due to the capacity of a-
tocopherol to inhibit STS-induced glutathione stock depletion.
Many authors have also demonstrated, in different cell types, that
accumulation of ROS is a critical effector of STS-induced
apoptosis [48,49]. Under such circumstances, antioxidants addi-
tion would be thought to protect cells from an excessive
production of ROS and consequently from apoptosis. So, to
determine whether tocopherol action was dependent on its
antioxidative properties, we evaluated the influence of other
ROS scavengers on STS-induced apoptosis. We demonstrated
that trolox, NAC, propofol and other antioxidants (Tempol and
Euk8) were unable to reverse, contrary to a-tocopherol, the
anticancer properties (both antiproliferative and apoptotic effects)
of STS. So, the inhibitory capacities of a-tocopherol on this kinase
inhibitor seem specific and cannot be extended to other
antioxidants. Obviously, a-tocopherol has other intrinsic proper-
ties and may act in an antioxidant-independent manner. This is
consistent with the fact that a-tocopherol, besides its well-known
antioxidant function, possesses non antioxidant properties that
have been explored by many other authors. Among them, the
inhibition of PKC seems of particular importance, as it is also a
target of STS. PKC possesses a regulatory (phospholipid and
phorbol ester binding site) and a catalytic domain (peptide and
ATP binding site) [46]. While STS is thought to be a direct ATP
competitive inhibitor on the catalytic domain, a-tocopherol seems
however to indirectly modulates PKC activity, by activating PP2A,
an enzyme that specifically dephosphorylates and deactivates
PKCa [6,10,50,51]. By doing that, a-tocopherol would likely be
able to interfere with STS action on PKC, even if added before
STS and not necessary together with the vitamin. To verify this
hypothesis, we evaluated the effect of a-tocopherol on STS-
induced cell cycle arrest using two patterns of drugs treatment: in
the first case (as all along the paper) STS and a-tocopherol were
added simultaneously and, in the second case, a pre-treatment
with atocopherol alone was done before STS addition (not shown).
Surprisingly, only the co-treatment with a-tocopherol was able to
inhibit the cell cycle arrest induced by STS, while the pre-
treatment with a-tocopherol was totally inefficient and unable to
reverse the STS effect on cell cycle. These results would rather
suggest a direct interaction between STS and a-tocopherol than a
competitive effect of these compounds on PKC. Furthermore the
ability of a-tocopherol to prevent the cytotoxicity of S37614 and
roscovitine, that do not target PKC but CDK, reinforces this
hypothesis.
STS constitutes a standard apoptotic inducer, but cannot be
used in clinical practice due to its non-selectivity and toxicity. For
this reason, we also tested benzoyl-STS (known as PKC412 or
midostaurin) an analog of STS, evaluated in clinical trials.
Benzoyl-STS has similar effects on cell growth than STS but
possesses a higher inhibitory specificity for PKC [29,30]. We
showed here that a-tocopherol exerts the same inhibitory
properties against benzoyl-STS than STS. Another molecule,
S37614 (Servier Laboratories) recently evaluated in preclinical
trials, has been then tested to enlarge our panel of kinases
inhibitors. As expected, S37614 inhibits cell growth of HeLa cell
line. And, similarly to STS and benzoyl-STS, the anticancer
effects of S37614 were counteracted by a-tocopherol. This
vitamin, that showed a good potency to block CDK-inhibitors
(S37614, roscovitin, flavopiridol), seems pretty efficient to hinder
the effects of kinase inhibitors in general. This led us to extend our
drug screening to kinase inhibitors used in clinical practice. This
class of molecules has recently been widely spread with the
introduction of targeted therapy in anticancer treatment protocols.
We evaluated the repercussions of a-tocopherol addition on (i)
imatinib and nilotinib treatment, two drugs used to inhibit the
oncogenic fusion protein BCR-ABL in CML and (ii) on gefitinib
effect, a well described EGFR inhibitor usually prescribed for non-
small cell lung cancer. The results totally corroborate the data
presented above, i.e. the presence of a-tocopherol in therapeutic
regimen used in clinical practice blocks the antiproliferative effect
of the drugs and compromises their beneficial action in vitro.T o
finally assess this specificity towards kinase inhibitors, we evaluated
the influence of the vitamin on apoptosis induced by a few other
anticancer drugs such as topoisomerase inhibitors and pro-
apoptotic compounds such as TNF-a. We demonstrated that a-
tocopherol had no effect and failed to protect cells from apoptosis
induced by camptothecin and etoposide, respectively known as
topoisomerase I and II inhibitors. And, identically, it has no
repercussions on TNF-a induced cell death, despite that a-
tocopherol has already been reported to protect U937 lymphoma
cells form this kind of treatment, but for a short term period [52].
Altogether, our data indicate that a-tocopherol would preferen-
tially target protein kinase inhibitors and impede their action. As it
remains inactive towards etoposide, camptothecin or TNF-a,w e
hypothesized that its effect would rather occur in the upstream
part of the death signalling pathway than in the downstream
common part shared by many drugs triggering apoptosis. As
displayed in Figure 6, we postulate that a-tocopherol may either
act inside or outside the cell. In the first case, it may specifically
block (i) the drug itself once incorporated into the cell, (ii) one of its
targets or (iii) a common partner induced upon protein kinase
inhibition, while in the second situation it would either change the
permeability of cellular membrane to some drugs or directly bind
to these latter. In both cases, this would prevent drugs from
exerting their effects.
In conclusion, we demonstrated that a-tocopherol inhibits STS
and more generally many kinase inhibitors anticancer effects,
while other antioxidants failed to, suggesting that a-tocopherol
engages different properties than its well-known antioxidant
activity. These in vitro data also emphasize the putative negative
effects of a-tocopherol supplementation on kinase inhibitors-based
anticancer therapy.
Materials and Methods
Reagents
a-tocopherol, benzoyl-staurosporine, euk8, NAC (N-acetyl-
cysteine), tempol and trolox were purchased from Calbiochem.
24 h (grey bars). Antioxidants (100 mM of tempol, 10 mM of SB203580, 100 mM of propofol, 100 mMo fa-tocopherol, 100 mM of trolox or 50 mMo f
euk8) were added simultaneously to STS. The percentage of cells in G0G1 phase was measured after propidium iodide staining and reported in the
graph. F Dose response functions was obtained for STS in response to a-tocopherol treatment (100 mM) in presence or not of cycloheximide (CHX
10 mM) in a clone of HeLa cells stably expressing a C3/7-DAP. EC50 values were determined and presented in the table below the dose-response
curves. G Growth curves of HeLa cells stained with DiI and treated with vehicle or 30, 100 and 300 mMo fa-tocopherol for 24, 48 and 72 hours.
Proliferation index was determined as described in the materials and methods section.
doi:10.1371/journal.pone.0036811.g003
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bonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone), flavopiridol, cy-
cloheximide, propofol, roscovitin and SB203580 were purchased
from Sigma-Aldrich. TNF-a was from Invitrogen. imatinib,
nilotinib and gefitinib were bought from Sequoia Research
Product. S37614 kinase inhibitor was a generous gift from
Servier’s Laboratory.
Figure 4. a-tocopherol blocks the anti-proliferative and pro-apoptotic properties of other kinase inhibitors independently of its
antioxidant capacities. A Benzoyl-STS dose-response curves in presence or absence of 100 mMo fa-tocopherol or 100 mM of trolox in a clone of
HeLa cells stably expressing a C3/7-DAP. EC50 values are shown below. B HeLa cells were treated with various concentrations of benzoyl-STS in
presence or not of 100 mMo fa-tocopherol or 100 mM of trolox, and stained for cell cycle profile. The percentage of cells in G2M is reported here.
C, D HeLa cells were treated with increasing amount of flavopiridol (C) or roscovitine (D) with or without 100 mMo fa-tocopherol for 24 hours. Cell
cycle profile was determined by flow cytometry using propidium iodide staining and the ratio of the percentage of cells in G2M on the percentage of
cells in G0G1 was calculated and reported. E S37614 dose-response curves in presence or absence of 100 mMo fa-tocopherol, 100 mM of trolox or
3 mM of NAC were determined using a clone of HeLa cells stably expressing a C3/7-DAP. F DiI-stained HeLa cells were treated with increasing
amounts of S37614 supplemented with vehicle or 100 mM of tocopherol, 100 mM of trolox or 3 mM of NAC. Cell proliferation dose response curves
were established from the median intensity fluorescence of DiI obtained for each point and normalized to the untreated control cells. EC50 values are
shown in the table below the curves.
doi:10.1371/journal.pone.0036811.g004
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HeLa (Human cervical cancer cells, ATCC # CCL-2), DU145
(Human prostate carcinoma cells, ATCC # HTB-81) cell lines
were grown in Dulbecco’s MEM medium (Gibco, Life technol-
ogies) supplemented with 10% fetal calf serum. K562 (Human
chronic myelogenous leukemia cells, # CCL-243) and PC-9
(Human adenocarcinoma from lung tissue, ECACC # 90071810)
cell lines were cultured in RPMI medium 1640 (Gibco, Life
technologies) supplemented with 10% fetal calf serum. All cell lines
were maintained at 37uC in a humidified atmosphere of 5% CO2/
95% air. Plasmid transfection and generation of DAPs (Differential
Anchorage probes) expressing stable clones were carried out as
previously described [27].
Figure 5. a-tocopherol prevents the action of kinase inhibitors used in clinical practice. A, B DiI-stained K562 cells were treated with
increasing amounts of imatinib or nilotinib (0, 3, 10 or 30 mM) supplemented with vehicle or 1 mMo fa-tocopherol. In each condition, cell proliferation
was followed according to the intensity of DiI staining after 24, 48 and 72 hours. Cells exhibiting a brighter DiI fluorescence than control cells divide
more slowly and are delayed in their cycle cell progression, while the ones having an equal or a weaker DiI intensity proliferate at the same rate or
faster than control cells. An example of DiI fluorescence intensity post-imatinib or nilotinib treatment (30 mM) in presence or absence of 1 mM a-
tocopherol is shown at each time point in A. The average DiI fluorescence intensity after all treatment is reported in panel B after normalization
(100% correspond to the DiI most intense cells). C PC-9 cells were treated with DMSO or 0.03 mM of Gefitinib in presence or absence of 100 mMo fa-
tocopherol and immediately transferred to the IncuCyte system for kinetic cell growth measurement. The percentage of cell growth corresponds to
the surface occupied by the cells in each well at each time point. D PC-9 cells were treated with DMSO or 0.03 mM of Gefitinib in presence or not of
100 mMo fa-tocopherol, and incubated in presence of SYTOX Green in the IncuCyte system for cell death measurement.
doi:10.1371/journal.pone.0036811.g005
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The principle of this technique, allowing the detection of
molecular events inside living cells such as caspase activation is
described in details in a previous article [27]. Practically, DAP
expressing cells were detached by trypsin, pooled and resuspended
in an intracellular saline solution supplemented with 50 mM
digitonin, 50 mM EGTA (ethylene glycol tetraacetic acid) and 4%
fetal calf serum. Cells were then analyzed on a FACSCalibur flow
cytometer (Becton Dickinson) equipped with an HTS (High
Throughput Sampler) module and a 488-nm argon ion excitation
laser. Fluorescence emission was measured in FL1 log mode.
Determination of Cytolysis
To evaluate cytolysis, cells were incubated on ice with 100 mLo f
extracellular saline solution (NaCl 130 mM, KCl 3.6 mM, Hepes
10 mM, NaHCO3 2 mM, NaH2PO4 0.5 mM, MgCl2,6 H 2O
0.5 mM, CaCl2,2 H 2O 1.5 mM, Glucose 4.5 g/l) supplemented
with 0.5 mg/mL ethidium monoazide bromide (EMA) for 10 min.
Then cells were exposed to a white light for 15 min. Cells were
then rinsed with 100 mL of extracellular saline solution for 5 min
and with PBS for 5 min. Cells were detached with trypsin/EDTA
and analysed by flow cytometry. EMA fluorescence was detected
in FL3 channel on a FACSCalibur flow cytometer (Becton
Dickinson) equipped with a 488-nm argon ion laser.
Determination of Proliferation Index and Monitoring of
Cell Proliferation (DiI Staining)
Before seeding, cells were incubated at 37uC in a solution of
5 mM DiI (1,19-dioctadecyl-3,3,39,39-tetramethylindocarbocyanine
perchlorate) and 0.3 M sucrose for 15 min under mild stirring.
Cells were rinsed twice, counted and seeded in 96-well microtiter
plates. The reference fluorescence value was measured at day 0 in
FL3 channel using a FACSCalibur flow cytometer. The median
intensity of DiI signal was then measured at day 1, 2 or 3. Values
were either directly plotted or used to determine the proliferation
index, corresponding to the ratio of DiI median intensity at day 0
on DiI median intensity at day 2 or 3.
Flow Cytometric Analysis of Cell Cycle
The stock solution of propidium iodide was first diluted at
50 mg/mL in an intracellular saline solution (NaCl 10 mM; KCl
130 mM; Hepes 20 mM; MgSO4,6 H 2O 1 mM; Succinate,6 H2O
5 mM) supplemented with 50 mM of digitonin and 50 mMo f
EGTA to permeabilize cellular membranes. After a pre-incuba-
Figure 6. Schematic representation of the potential non-antioxidant properties of a-tocopherol on different pharmacological
classes of anticancer drugs. Two hypotheses may be arisen in regards to the non-antioxidant protective role of a-tocopherol against the action of
preclinical and clinical protein kinase inhibitors. The vitamin may either act outside the cells by preventing the different drugs to enter within the cell
(extracellular effects) or inside by blocking the signalling pathway leading to death (intracellular effect). In the first case, we could imagine that a-
tocopherol directly binds to the cytotoxic compounds or change the permeability of the cytoplasmic membrane to render it impermeable to this
kind of inhibitors. In the second case, a-tocopherol would either directly act on (i) the kinase inhibitor, (ii) their targets or (iii) a common signalling
partner engaged upon kinase inhibitors treatment and supposedly leading to death (=‘‘x’’ protein).
doi:10.1371/journal.pone.0036811.g006
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added to the cells for 1 h at 4uC. PI signal was detected in FL3
channel by flow cytometry.
ROS Level Measurement
ROS levels were quantified using a solution of dichloro-
dihydro-fluoresceine-diacetate (H2DCFDA), as described in the
manufacturer’s protocol (Invitrogen). Briefly, after trypsinisation,
HeLa cells were incubated in presence of 20 mM of H2DCFDA.
After 20 min at 37uC, ROS were quantified by flow cytometric
analysis in FL1 channel using a FACSCalibur flow cytometer.
Immunoblot Analysis
Hela cells were seeded in a 6 well-plate at 3610
5 cells/well and
incubated with vehicle or 100 nM of STS in absence or presence
of 100 mM of tocopherol, 10 mM of NAC or 50 mM of zVAD for
24 hours. Cells were then rinsed in PBS, pelleted and resuspended
in 40 ml of lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-
40, pH8) supplemented with a cocktail of protease inhibitors
(Complete Mini-EDTA-free, Roche). After 1 hour at 4uC, lysed
cells were spun down at 13 200 rpm for 15 min and all
supernatants were collected. Protein concentration has been
determined using the Bio-Rad Protein Assay kit (Bio-Rad
laboratories GmbH, Mu ¨nchen, Deutschland). 50 mg of proteins
were separated by electrophoresis on a 10% SDS polyacrylamide
gel and transferred onto a PVDF (polyvinylidene fluoride)
membrane (NEN Life Science Product, Boston, MA). Membrane
was blocked 1 hour in PBST (phosphate buffered saline Tween 20)
containing 5% low fat dry milk and probed with primary antibody
diluted in TBST (Tris buffered saline Tween 20) with 5% BSA for
anti-cleaved PARP antibody (1/1000; Cell Signaling, # 5625S) or
PBST with 2.5% low fat dry milk for anti-actin antibody (1/1000;
Sigma) overnight at 4uC. Membrane was then washed 4 times with
TBST (for anti-PARP) or PBST (for anti-actin), incubated with
horseradish peroxidase (HRP)-conjugated anti-rabbit secondary
antibody (1/5000) for 1 hour at room temperature. After washing
4 times with TBST or PBST, protein bands were visualized using
the Immobilon Western Detection System (Millipore) and
quantified using ImageJ software.
Imaging
Cells were seeded onto glass coverslips in 24-well plates the day
prior drug treatment, and fixed 24 hours later with 3.7%
formaldehyde for 10 min at room temperature (RT). After three
washes in PBS, cells were incubated for 10 min with a solution of
NH4Cl (50 mM) and immediately rinsed three times in PBS.
Nuclear staining was done with a 1/5000 dilution of Hoechst
33258 (10 mg/ml) (Molecular Probes) for 10 min at RT.
Coverslips were washed once in PBS and then mounted with
Fluoromount G on glass slides. Image acquisition was performed
using a Zeiss LSM 510 Meta microscope.
Live-cell Kinetic Assays for Cell Proliferation and Cytolysis
5610
3 PC-9 cells were seeded into each well of a 96-well-plate
and treated 24 hours later with gefitinib in presence or not of
100 mMo fa-tocopherol. Cells were immediately transferred into
the IncuCyte
TM real-time imaging system (Essen Instruments) to
follow kinetic cell proliferation and cytolysis. For cell growth
measurement, high quality non-labelled phase-contrast images
were acquired and automatically processed by a contrast-based
confluence algorithm to determine the surface occupied by the
cells in the well for each image at each time point. This value of
cell confluence was then plotted to generate cell growth curves.
For cytotoxicity measurement, cells were stained with SYTOX
Green Nucleic Acid Stain (Invitrogen S7020) before being placed
in the Incucyte system that also permits the acquisition of
fluorescent images. The number of fluorescent cytolysed cells per
image was determined for each image at each time point. In all
cases, images were acquired every 2 hours for 70 hours.
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